A novel RNA-based therapy developed at Columbia University is showing promise in enhancing the heart’s natural ability to heal after a heart attack, potentially offering a less invasive treatment option for patients. The research, published in Science, centers around a single injection that could significantly reduce scarring and improve heart function, a critical step toward addressing the long-term consequences of cardiac events.
Heart attacks cause irreversible damage to muscle cells, leaving many patients with debilitating heart failure. While cardiologists can restore blood flow to blocked vessels, the heart’s limited regenerative capacity means damaged tissue is rarely replaced. This new approach aims to change that, leveraging the body’s own mechanisms to promote healing. “The heart is one of the organs with the least ability to regenerate,” explained Ke Cheng, Alan L. Kaganov Professor of Biomedical Engineering at Columbia Engineering. “The spontaneous regeneration power is particularly, very limited.”
Harnessing the Power of RNA
The therapy utilizes RNA-lipid nanoparticles designed to instruct muscle cells in the arm or thigh to produce a molecule called pro-ANP. This inactive precursor travels through the bloodstream, ultimately being converted into the active hormone atrial natriuretic peptide (ANP) by an enzyme called Corin within the heart. ANP is known to promote healing by encouraging new blood vessel growth, reducing inflammation, and limiting scar formation. “You don’t have to open the chest or send a wire to the heart to deliver this drug,” Cheng stated. “In principle, all the clinician needs to do is to inject the particles into the arm.”
Credit: Cheng Lab/Columbia University
Inspired by the Neonatal Heart
The research draws inspiration from the remarkable regenerative abilities observed in newborn mammals. During the first few days of life, a young heart possesses a brief window of opportunity to repair damaged muscle cells. Experiments revealed that newborn hearts exhibit a significantly higher expression of the gene responsible for producing the ANP precursor – more than 25-fold compared to adults, where the increase is only about tenfold. Blocking this gene in newborn mice diminished their natural healing capabilities, highlighting its crucial role. “The whole idea is that we learn from nature,” Cheng said. “The neonatal heart spontaneously produces more of this molecule after a heart attack. That’s probably why young hearts can regenerate themselves. The adult can’t produce a sufficient amount so we found a way to supplement this to the heart.”
A Minimally Invasive Approach
Traditional methods of delivering drugs directly to the heart have been challenging, often requiring invasive procedures like injections into the heart muscle or blood vessels. Torsten Vahl, a co-author and cardiologist at Columbia University Irving Medical Center/New York-Presbyterian Hospital, emphasized the potential of this new approach to fill a critical gap in cardiac care. “As a clinician who opens up arteries with stents for patients who come to us with heart attacks, I am highly aware that we have a large unmet need for our patients,” Vahl said. “Too many times they are left with severe heart damage that results later in heart failure.” This new method circumvents those challenges by utilizing skeletal muscle as a “drug factory,” releasing pro-ANP into the bloodstream for conversion within the heart.
The therapy utilizes self-amplifying RNA, meaning a single injection can provide therapeutic effects for at least four weeks. Laboratory studies demonstrated that a single injection reduced scarring and improved heart function in various animal models, including those with pre-existing conditions like atherosclerosis and type 2 diabetes. The treatment remained effective even when administered a week after a simulated heart attack, suggesting a potential window of opportunity for intervention.
Beyond Heart Attacks: Potential for Broader Applications
Researchers believe the potential of this RNA-based strategy extends beyond heart attacks. “Cell damage is a problem that not only affects the heart but many organs,” Vahl noted. The same approach could potentially be adapted to treat conditions like kidney disease, high blood pressure, and preeclampsia. Cheng’s team is now focused on manufacturing the therapy at the Columbia Initiative in Cell Engineering and Therapy and initiating a Phase I safety trial at Columbia University Irving Medical Center. “We can leverage our in-house resources for manufacturing and then start a clinical trial,” Cheng said. “Columbia can do both.”
The development of this RNA therapy represents a significant step forward in cardiac care, offering a potentially less invasive and more effective way to help hearts heal. While further research and clinical trials are necessary, the initial findings provide a hopeful outlook for patients facing the challenges of heart damage and failure.
What are your thoughts on this new approach to heart repair? Share your comments below, and please share this article with anyone who might find it informative.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
